Search Results for: STAT3

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
EIF2AK2 eukaryotic translation initiation factor 2 alpha kinase 2
  • ISG15 antiviral mechanism
  • Inhibition of PKR
  • SUMOylation of immune response proteins
  • Interferon alpha/beta signaling
  • Evasion by RSV of host interferon responses
  • PKR-mediated signaling
  • Indomethacin
  • H-89
  • Fostamatinib
ELP2 elongator acetyltransferase complex subunit 2
  • HATs acetylate histones
EP300 EP300 lysine acetyltransferase
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Polo-like kinase mediated events
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • B-WICH complex positively regulates rRNA expression
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • Metalloprotease DUBs
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • STAT3 nuclear events downstream of ALK signaling
  • Heme signaling
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • Nuclear events mediated by NFE2L2
  • Formation of paraxial mesoderm
  • NFE2L2 regulating inflammation associated genes
  • NFE2L2 regulating anti-oxidant/detoxification enzymes
  • NFE2L2 regulates pentose phosphate pathway genes
  • NFE2L2 regulating tumorigenic genes
  • NFE2L2 regulating MDR associated enzymes
  • NFE2L2 regulating ER-stress associated genes
  • Regulation of NFE2L2 gene expression
  • Regulation of NFE2L2 gene expression
  • Zygotic genome activation (ZGA)
  • Evasion by RSV of host interferon responses
  • TGFBR3 expression
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
  • Rubinstein-Taybi syndrome
EPHA3 EPH receptor A3
  • EPH-Ephrin signaling
  • EPH-Ephrin signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • EPH-ephrin mediated repulsion of cells
  • Fostamatinib
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Developmental Lineage of Mammary Stem Cells
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Breast cancer
  • Cervical cancer
  • Cholangiocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Ovarian cancer
  • Choriocarcinoma
  • Endometrial Cancer
  • Bladder cancer
ERBIN erbb2 interacting protein
  • Signaling by ERBB2
  • Downregulation of ERBB2 signaling
  • RHOA GTPase cycle
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOG GTPase cycle
  • RAC3 GTPase cycle
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
ESR1 estrogen receptor 1
  • Nuclear signaling by ERBB4
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Ovarian tumor domain proteases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • RUNX1 regulates estrogen receptor mediated transcription
  • ESR-mediated signaling
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • Mitochondrial unfolded protein response (UPRmt)
  • Developmental Lineage of Mammary Gland Luminal Epithelial Cells
  • Developmental Lineage of Mammary Gland Alveolar Cells
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated estrogens
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Lindane
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone acetate
  • Testosterone
  • Mitotane
  • Estrone
  • Tamoxifen
  • Hexachlorophene
  • Estradiol
  • Ethynodiol diacetate
  • Dobutamine
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinylestradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Oxybenzone
  • Allylestrenol
  • Zinc
  • Genistein
  • Prasterone
  • Benzophenone
  • Equilin
  • Compound 19
  • Resveratrol
  • Compound 18
  • Phthalic Acid
  • Pyrazole
  • Stanolone
  • Naringenin
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Quercetin
  • Afimoxifene
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estrone sulfate
  • Quinestrol
  • Phenolphthalein
  • Permethrin
  • Ospemifene
  • AP1081
  • Custirsen
  • NP-50301
  • CHF 4227
  • TAS-108
  • Lasofoxifene
  • Arzoxifene
  • Elacestrant
  • Bazedoxifene
  • Methyltestosterone
  • beta-Naphthoflavone
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • din-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • Hexestrol
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • Erteberel
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • 2-(4-hydroxyphenyl)benzo[b]thiophen-6-ol
  • Tibolone
  • Eugenol
  • Synthetic Conjugated Estrogens, A
  • Synthetic Conjugated Estrogens, B
  • Polyestradiol phosphate
  • Norethynodrel
  • Octocrylene
  • Homosalate
  • Enzacamene
  • Zeranol
  • Ractopamine
  • Gestrinone
  • Estetrol
  • Propyl Gallate
  • Ormeloxifene
  • 2-Methoxy-6-{(E)-[(4-methylphenyl)imino]methyl}phenol
  • Testosterone cypionate
  • Testosterone enanthate
  • Stanolone acetate
  • Estradiol acetate
  • Estradiol benzoate
  • Estradiol cypionate
  • Estradiol dienanthate
  • Estradiol valerate
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Estriol tripropionate
  • Fluoroestradiol F-18
FAM117B family with sequence similarity 117 member B
FBXW7 F-box and WD repeat domain containing 7
  • Association of TriC/CCT with target proteins during biosynthesis
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
FER FER tyrosine kinase
  • Signaling by SCF-KIT
  • Fostamatinib
FES FES proto-oncogene, tyrosine kinase
  • Signaling by SCF-KIT
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • Fostamatinib
FGFR3 fibroblast growth factor receptor 3
  • Signaling by activated point mutants of FGFR3
  • t(4;14) translocations of FGFR3
  • Signaling by FGFR3 in disease
  • Signaling by FGFR3 fusions in cancer
  • XL999
  • Pazopanib
  • Ponatinib
  • Lenvatinib
  • Nintedanib
  • Infigratinib
  • Fostamatinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
  • Selpercatinib
  • CATSHL syndrome
  • Multiple myeloma
  • FGFR3-related short limb skeletal dysplasias, including: Achondroplasia; Hypochondroplasia; Thanatophoric dysplasia, type 1; Thanatophoric dysplasia, type 2; Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN)
  • Lacrimo-auriculo-dento-digital syndrome (LADD); Levy-Hollister syndrome
  • Craniosynostosis, including: Pfeiffer syndrome; Apert syndrome; Crouzon syndrome; Jackson-Weiss syndrome; Beare-Stevenson syndrome; Muenke craniosynostosis; Saethre-Chotzen syndrome; Craniosynostosis Boston type; Antley-Bixler syndrome; Carpenter syndrome; Craniofrontonasal dysplasia; Noonan syndrome; Baller-Gerold syndrome
  • Bladder cancer
FGFR4 fibroblast growth factor receptor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • betaKlotho-mediated ligand binding
  • FGFR4 mutant receptor activation
  • FGFR4 ligand binding and activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR4
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR4 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Heparin
  • Ponatinib
  • Lenvatinib
  • Infigratinib
  • Erdafitinib
  • Pemigatinib
  • Futibatinib
FGR FGR proto-oncogene, Src family tyrosine kinase
  • FCGR activation
  • Platelet sensitization by LDL
  • Neutrophil degranulation
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Dasatinib
  • Fostamatinib
  • Zanubrutinib
FHL2 four and a half LIM domains 2
  • PPARA activates gene expression
FLT1 fms related receptor tyrosine kinase 1
  • Neurophilin interactions with VEGF and VEGFR
  • VEGF binds to VEGFR leading to receptor dimerization
  • Sorafenib
  • Sunitinib
  • Vatalanib
  • TG-100801
  • OSI-930
  • Denibulin
  • Linifanib
  • IMC-1C11
  • Pazopanib
  • Axitinib
  • N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide
  • Regorafenib
  • Lenvatinib
  • Nintedanib
  • Polaprezinc
  • Foreskin fibroblast (neonatal)
  • Tivozanib
  • Fostamatinib
  • Selpercatinib
FOXM1 forkhead box M1
  • Polo-like kinase mediated events
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Nuclear events stimulated by ALK signaling in cancer
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • Co-inhibition by CTLA4
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Dasatinib
  • Triglyme
  • Fostamatinib
  • Zotiraciclib
GAS5 growth arrest specific 5
GATA1 GATA binding protein 1
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Factors involved in megakaryocyte development and platelet production
  • Congenital dyserythropoietic anemias (CDAs)
  • Thrombocytopenia (THC); Familial platelet disorder with associated myeloid malignancy (FPDMM)

Page 3 out of 11 pages